AI Article Synopsis
- * The newly created compounds were tested for their ability to inhibit the activation of the Epstein-Barr virus-early antigen (EBV-EA) triggered by a specific chemical (TPA).
- * Among the tested compounds, 6d showed significant inhibitory activity, while 5a and 6e also demonstrated effectiveness.
Article Abstract
As a continuation to our previous work concerning antitumor benzimidazoles, we have synthesized series of new derivatives of 2-(1-benzyl-2-methyl-1H-benzimidazol-5-ylimino)-3-(substituted)-thiazolidin-4-one (6a-e), 3-(2-methyl-1H-benzimidazol-5-yl)-2-substituted-thiazolidin-4-one (9a-f) and we have studied their inhibitory activity against the Epstein-Barr virus-early antigen (EBV-EA) activation introduced by 12-O-tetradecanoylphorbol-13-acetate (TPA). Compound 6d was found to be significantly active and compounds 5a and 6e were also active.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmc.2007.04.010 | DOI Listing |
Publication Analysis
Top Keywords
inhibitory activity
8
synthesis inhibitory
4
activity benzimidazole
4
benzimidazole derivatives
4
derivatives burkitt's
4
burkitt's lymphoma
4
lymphoma promotion
4
promotion continuation
4
continuation previous
4
previous work
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!